SINOCHEM INTERNATIONAL(SH:600500)2022-10-28 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥21,526,482,592.19, representing a 10.56% increase compared to ¥19,416,826,204.58 in the same period last year[8]. - Net profit attributable to shareholders was ¥315,441,479.35, a 21.01% increase from ¥263,803,066.99 year-on-year[8]. - The basic earnings per share increased to ¥0.11, up 37.5% from ¥0.08 in the previous year[8]. - The net profit attributable to shareholders for the first three quarters of 2022 was ¥1,289,781,591.26, a decrease of 46.36% compared to the previous year[11]. - The company reported a 27% increase in revenue and an 80% increase in net profit attributable to shareholders when excluding the impact of the sale of Jiangsu Yangnong Chemical Co., Ltd. shares in the previous year[11]. - The company's net profit attributable to shareholders increased to ¥7,892,172,730.32 from ¥6,872,919,520.27, marking a growth of around 14.8%[41]. - The company's net profit for the third quarter of 2022 was approximately CNY 2.03 billion, a decrease from CNY 6.61 billion in the same period of 2021, representing a decline of about 69%[48]. - Operating profit for the third quarter was CNY 2.69 billion, down from CNY 9.57 billion year-over-year, indicating a decrease of approximately 72%[48]. - The company reported a total comprehensive income of CNY 1.71 billion for the third quarter, down from CNY 6.34 billion in the previous year, marking a decline of approximately 73%[48]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥66,717,754,833.31, marking a 15.08% increase from ¥57,973,201,813.52 at the end of the previous year[10]. - The company's total liabilities grew to ¥45,489,722,905.80 from ¥38,043,780,010.74, indicating an increase of around 19.4%[41]. - Short-term borrowings increased significantly to ¥10,166,405,646.24 from ¥7,676,723,495.59, representing a rise of about 32.5%[39]. - Long-term borrowings also saw a substantial increase, reaching ¥12,791,087,031.39, up from ¥9,260,928,473.07, which is an increase of approximately 38.5%[39]. - The company's current assets totaled ¥21,452,836,253.27, with significant components including accounts receivable of ¥3,679,760,457.14 and inventory of ¥7,594,505,990.67[58]. - The total liabilities reached ¥38,043,780,010.74, with current liabilities accounting for ¥26,455,843,401.43, including short-term borrowings of ¥7,676,723,495.59[61]. Cash Flow and Investments - Net cash flow from operating activities significantly improved compared to the previous year due to enhanced operational efficiency[22]. - The net cash flow from operating activities for the first nine months of 2022 was CNY 2.69 billion, a significant recovery from a negative cash flow of CNY -2.05 billion in the same period of 2021[52]. - The company reported a net cash outflow from investing activities of CNY 6.95 billion for the first nine months of 2022, compared to a smaller outflow of CNY 178.53 million in the same period of 2021[52]. - The company raised CNY 46.28 billion through borrowings in the first nine months of 2022, compared to CNY 39.57 billion in the same period of 2021, indicating a growth of approximately 17%[53]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 69,090[24]. - China National Chemical Corporation held 54.23% of shares, making it the largest shareholder[24]. Operational Efficiency - The company is focused on enhancing operational efficiency and improving working capital turnover[22]. - The company has implemented new accounting standards affecting the recognition of revenue and costs related to trial sales of products[12]. Research and Development - Research and development expenses amounted to ¥702,361,361.76, slightly higher than ¥684,531,505.70 in the previous year, reflecting a year-over-year increase of approximately 2.4%[42].